gaboxadol has been researched along with Neurodevelopmental Disorders in 1 studies
gaboxadol: GABA agonist; inhibitor of GABA uptake systems; structure
Neurodevelopmental Disorders: These are a group of conditions with onset in the developmental period. The disorders typically manifest early in development, often before the child enters grade school, and are characterized by developmental deficits that produce impairments of personal, social, academic, or occupational functioning. (From DSM-5).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Copping, NA | 1 |
| McTighe, SM | 1 |
| Fink, KD | 1 |
| Silverman, JL | 1 |
1 review available for gaboxadol and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome.
Topics: Angelman Syndrome; Animals; Anticonvulsants; Biological Products; Genetic Therapy; Humans; Isoxazole | 2021 |